Document is current
Any future updates will be listed below
-
Authors
Tjeerdsma, Rinskje B. https://orcid.org/0009-0000-1175-8333
Ng, Timothy F.
Roorda, Maurits
Bianchi, Daniëlle
Yang, Sora
Bonnet, Clara https://orcid.org/0000-0002-9197-485X
VanInsberghe, Michael https://orcid.org/0000-0001-8418-4393
Everts, Marieke
Bakker, Femke J. https://orcid.org/0000-0002-6078-8333
de Boer, H. Rudolf https://orcid.org/0000-0002-8386-8184
Moatti, Nathalie
Hustedt, Nicole
Yin, Jay Z
Hoeg, Lisa
Leibovitch, Matthew
Sicheri, Frank https://orcid.org/0000-0002-9824-2117
van Oudenaarden, Alexander https://orcid.org/0000-0002-9442-3551
de Jong, Steven https://orcid.org/0000-0001-5831-6997
van den Berg, Jeroen https://orcid.org/0000-0002-9430-7155
Tanenbaum, Marvin E. https://orcid.org/0000-0001-8762-0090
Brummelkamp, Thijn R. https://orcid.org/0000-0002-3066-7071
Durocher, Daniel https://orcid.org/0000-0003-3863-8635
van Vugt, Marcel A.T.M. https://orcid.org/0000-0002-3202-4678
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (KWF-11352)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (09150182110019)
EC | Horizon 2020 Framework Programme (101053581)
Novo Nordisk Fonden ((#0091873)
Gouvernement du Canada | Canadian Institutes of Health Research (PJT 180438)
- License Information
-
More Information
Article History
Received: 11 March 2025
Accepted: 6 November 2025
First Online: 24 November 2025
Competing interests
: D.D. and F.S. are shareholders and advisors for Repare Therapeutics. M.A.T.M.v.V. acted on the Scientific Advisory Board of Repare Therapeutics. The remaining authors declare no competing interests.
